Shire sues US firm over epilepsy drug
Thursday 15 January 2004
Shire Pharmaceuticals has launched a lawsuit against Nostrum Pharmaceuticals after it made public plans to launch a similar version of Shire's epilepsy drug Carbatrol.
Nostrum, a privately owned company based in New Jersey, filed a new drug application for a generic version of the 300mg dosage strength of Carbatrol.
Shire, which launched its Carbatrol drug in 1998, said it had served Nostrum with a complaint for patent infringement but would not go into details. A spokeswoman said its patents on the drug - which has made about $164m of sales since its launch - did not expire until 2016. "Our lawyers have looked at the dossier [from Nostrum that has been filed with the US Food & Drug Administration] and believe it infringes patents," she said.
The move is not a great surprise, however, since the FDA announced last summer that an unnamed drug manufacturer had asked it to approve a copycat version of Shire's epilepsy treatment.
Carbatrol is one of Shire's main drugs and produced sales of $11.6m in the third quarter of last year. The company estimates it has about a 40 per cent market share.
The spokeswoman also said yesterday that the filing centred only on the 300mg strength of the drug and did not affect its 100mg or its 200mg products.
The 300mg strength, she said, made up about half the total sales Shire has so far recorded from Carbatrol.
The company's response to Nostrum's filing triggers a 30-month stay of approval - meaning the earliest date a generic version of the drug could be launched, if cleared by the court, is January 2006.
Shire's biggest selling drug is its hyperactivity drug Adderall XR, which accounts for about half of its sales. It is also battling to prevent generic versions of that drug hitting the market. At the end of last year, it announced it was suing the US drug maker Impax, which signalled it was developing a copy of Adderall XR. It has already launched proceedings against Barr, another US company developing generic Adderall.
- 1 Nathan Collier: Montana man inspired by same-sex marriage ruling requests right to wed two wives
- 2 Amber Roof: Sister of Charleston shooting suspect Dylann Roof launches fund-raising appeal for wedding and honeymoon
- 3 'Help me I'm trapped in a factory' messages keep being found on bottles of vitamin water
- 4 Right to die: Belgian doctors rule depressed 24-year-old woman has right to end her life
- 5 BP hit with record $18.7 billion fine over Deepwater Horizon Gulf oil spill
Nathan Collier: Montana man inspired by same-sex marriage ruling requests right to wed two wives
Amber Roof: Sister of Charleston shooting suspect Dylann Roof launches fund-raising appeal for wedding and honeymoon
Russell Brand condemns moment of silence for Tunisia attack victims as a 'minute of bulls**t'
Right to die: Belgian doctors rule depressed 24-year-old woman has right to end her life
Worker killed by robot at Volkswagen car factory
Greece crisis: IMF was pushed around by Angela Merkel and Nicholas Sarkozy – and now it is being humiliated
Forget little green men – aliens will look like humans, says Cambridge University evolution expert
'I wish the BBC would stop calling it Islamic State' – David Cameron unleashes frustration at broadcaster
Greece crisis: The wider lesson is that it’s time to abandon this failed experiment in currencies
Girl, 7, stares down hate preacher at Ohio festival with pro-LGBT rainbow flag gesture
They are neither a 'state' nor 'Islamic': Why we shouldn't call them Isis, Isil or IS
iJobs Money & Business
£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...
£15000 - £16000 per annum: Recruitment Genius: Customer Service Advisors are r...
£20000 - £25000 per annum + OTE £45K: SThree: SThree were established in 1986....
£40000 - £60000 per annum: Recruitment Genius: A Compliance Manager is require...